Newsletter sign-up

Marketing permissions

Reapplix ApS will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please confirm by ticking the below box and clicking the Subscribe button further down:

American Diabetes Association Meeting, Orlando
Friday, 22 June 2018

We look forward to attending this conference, where the results of the large scale Randomised Controlled trial with our technology will be presented in public for the first time by the Principle Investigators in the study.

  • Key patents granted in Europe and Eurasia

    Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification that key patents have been granted in Europe and in Eurasia.

  • Patent news – Patent granted in Japan

    Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification that a key patent has been granted in the Japan.

  • Patent news – Patents granted in China and Canada

    Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification of key patents grants in China and Canada.

  • Study Shows Effectiveness of LeucoPatch in Healing Diabetic Foot Ulcers

    A newly published study using LeucoPatch, a unique active wound therapy, developed by Reapplix ApS (Reapplix), has been published showing that LeucoPatch was highly effective in healing diabetic foot ulcers.

  • Reapplix Patents Granted in USA and Japan

    Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification that key patents have been granted in the United States and in Japan.

  • REAPPLIX ANNOUNCED AS INNOVATION PRIZE WINNER 2014 IN 'THE ENGINEER'

    Reapplix was today announced as the winner of ‘The Engineer’ Product Prize 2014 in the Innovation category. The Engineer’s Product Prize is a prestigious award recognising technologically advanced products that are both novel and are based on significant technical skills and knowledge.

    Commenting on the award, the judges stated that “LeucoPatch solves a significant problem among diabetics. It is simple to use and it utilizes the body’s own biology. The product reflects thorough research and has very significant knowledge built into it. Therefore, it wins the Innovation Award.”

  • REAPPLIX - 2014 EY ENTREPRENEUR OF THE YEAR FINALIST

    Reapplix was chosen from the selected participants in the 2014 EY Entrepreneur Of The Year in Denmark as a top 3 finalist in the Life Sciences category. This provided the opportunity to showcase both the company and the LeucoPatch technology in a short film presented to industry and business leaders assembled at the prestigious EY Entrepreneur Of The Year awards event in Copenhagen on 27 November 2014.

  • CMS approves Reapplix clinical study for reimbursement coverage

    Reapplix announces that the Centers for Medicare and Medicaid Services in the USA have approved Reapplix’s clinical research study protocol for Coverage with Evidence Development.

  • Reapplix announces appointment of Graeme Brookes as new CEO

    Reapplix ApS (Reapplix), developers of the unique LeucoPatch active wound therapy, have appointed Graeme Brookes as Chief Executive Officer.

  • LeucoPatch support the work of the diabetic foot study group

Page 2 of 3 Previous Next
Top